Resolvin D1 Limits Polymorphonuclear Leukocyte Recruitment to Inflammatory Loci: Receptor-Dependent Actions

Objective—Resolvin D1 (RvD1) limits neutrophil recruitment during acute inflammation and is derived from omega-3 docosahexaenoic acid to promote catabasis. The contribution of its specific receptors, the lipoxin A4/Annexin-A1 receptor formyl-peptide receptor 2 (FPR2/ALX) and the orphan receptor G-protein–coupled receptor 32 (GPR32) are of considerable interest. Methods and Results—RvD1 reduced human polymorphonuclear leukocytes recruitment to endothelial cells under shear conditions as quantified using a flow chamber system. Receptor-specific antibodies blocked these anti-inflammatory actions of RvD1, with low (1 nmol/L) concentrations sensitive to GPR32 blockade, while the higher (10 nmol/L) concentration appeared FPR2/ALX-specific. Interestingly, polymorphonuclear leukocytes surface expression of FPR2/ALX but not GPR32 increased following activation with pro-inflammatory stimuli, corresponding with secretory vesicle mobilization. Lipid mediator metabololipidomics carried out with 24-hour exudates revealed that RvD1 in vivo gave a significant reduction in the levels of a number of pro-inflammatory mediators including prostaglandins and leukotriene B4. These actions of RvD1 were abolished in fpr2 null mice. Conclusion—Pro-resolving lipid mediators and their receptors, such as RvD1 and the 2 G-protein–coupled receptors, studied here regulate resolution and may provide new therapeutic strategies for diseases with a vascular inflammatory component.

[1]  Charles N. Serhan,et al.  Molecular circuits of resolution: formation and actions of resolvins and protectins , 2005, The Journal of Immunology.

[2]  C. Clish,et al.  Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues. , 1998, The Journal of clinical investigation.

[3]  C. Serhan,et al.  Resolvin D1 binds human phagocytes with evidence for proresolving receptors , 2010, Proceedings of the National Academy of Sciences.

[4]  K. Urabe,et al.  Antiinflammatory mediator lipoxin A4 and its receptor in synovitis of patients with rheumatoid arthritis. , 2007, The Journal of rheumatology.

[5]  M. Toner,et al.  Rapid Appearance of Resolvin Precursors in Inflammatory Exudates: Novel Mechanisms in Resolution1 , 2008, The Journal of Immunology.

[6]  Adriano G. Rossi,et al.  Inflammatory Resolution: new opportunities for drug discovery , 2004, Nature Reviews Drug Discovery.

[7]  M. Cybulsky,et al.  Getting to the site of inflammation: the leukocyte adhesion cascade updated , 2007, Nature Reviews Immunology.

[8]  J. Uddin,et al.  Resolvin D1 and Its Aspirin-triggered 17R Epimer , 2007, Journal of Biological Chemistry.

[9]  C. Serhan,et al.  Resolvin E1 Regulates Adenosine Diphosphate Activation of Human Platelets , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[10]  J. Falloon,et al.  Neutrophil granules in health and disease. , 1986, The Journal of allergy and clinical immunology.

[11]  D. Gilroy,et al.  Dichotomy in duration and severity of acute inflammatory responses in humans arising from differentially expressed proresolution pathways , 2010, Proceedings of the National Academy of Sciences.

[12]  H. Heng,et al.  Cloning genes encoding receptors related to chemoattractant receptors. , 1998, Genomics.

[13]  C. Serhan,et al.  Metabolomics‐Lipidomics of Eicosanoids and Docosanoids Generated by Phagocytes , 2011, Current protocols in immunology.

[14]  A. Simopoulos.  Omega-3 Fatty Acids in Inflammation and Autoimmune Diseases , 2002, Journal of the American College of Nutrition.

[15]  Takao Shimizu,et al.  The Lipoxin Receptor ALX: Potent Ligand-Specific and Stereoselective Actions in Vivo , 2006, Pharmacological Reviews.

[16]  J. Werba,et al.  Transcriptional regulation of the human FPR2/ALX gene: evidence of a heritable genetic variant that impairs promoter activity , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  Larry V. McIntire,et al.  Leucocyte adhesion under flow conditions: principles important in tissue engineering. , 1996, Biomaterials.

[18]  J. Takeda,et al.  The Anti-Inflammatory and Proresolving Mediator Resolvin E1 Protects Mice from Bacterial Pneumonia and Acute Lung Injury , 2009, The Journal of Immunology.

[19]  R. Hannon,et al.  Anti-Inflammatory Role of the Murine Formyl-Peptide Receptor 2: Ligand-Specific Effects on Leukocyte Responses and Experimental Inflammation , 2010, The Journal of Immunology.

[20]  A. Hashimoto,et al.  Glucocorticoids co-interact with lipoxin A4 via lipoxin A4 receptor (ALX) up-regulation. , 2007, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[21]  D. McKay,et al.  Aspirin-triggered lipoxin enhances macrophage phagocytosis of bacteria while inhibiting inflammatory cytokine production. , 2011, American journal of physiology. Gastrointestinal and liver physiology.

[22]  Ji Min Kim,et al.  Chemical Mediators of Inflammation and Resolution in Post-Operative Abdominal Aortic Aneurysm Patients , 2012, Inflammation.

[23]  C. Clish,et al.  Novel Functional Sets of Lipid-Derived Mediators with Antiinflammatory Actions Generated from Omega-3 Fatty Acids via Cyclooxygenase 2–Nonsteroidal Antiinflammatory Drugs and Transcellular Processing , 2000, The Journal of experimental medicine.

[24]  Carl Nathan,et al.  Nonresolving Inflammation , 2010, Cell.

[25]  C. Serhan,et al.  Impaired Phagocytosis in Localized Aggressive Periodontitis: Rescue by Resolvin E1 , 2011, PloS one.

[26]  Charles N. Serhan,et al.  Resolvin E1 and protectin D1 activate inflammation-resolution programmes , 2007, Nature.

[27]  John Savill,et al.  Resolution of inflammation: the beginning programs the end , 2005, Nature Immunology.

[28]  M. Perretti,et al.  FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin‐derived peptide‐stimulated phagocytosis , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  Charles N. Serhan,et al.  Lipid mediator class switching during acute inflammation: signals in resolution , 2001, Nature Immunology.

[30]  Sriram Krishnamoorthy,et al.  MicroRNAs in resolution of acute inflammation: identification of novel resolvin Dl‐miRNA circuits , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  C. Serhan,et al.  Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  C. Serhan,et al.  Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host defense , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  K. Swedberg.  n-3 Fatty acids in cardiovascular disease. , 2011, The New England journal of medicine.

[34]  Marc Parmentier,et al.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the Formyl Peptide Receptor (FPR) Family , 2009, Pharmacological Reviews.

[35]  M. Perretti,et al.  Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis , 2009, Nature.

[36]  Sheng-hua Wu,et al.  Elevated expressions of 15-lipoxygenase and lipoxin A4 in children with acute poststreptococcal glomerulonephritis. , 2009, The American journal of pathology.

[37]  M. Perretti,et al.  Therapeutic anti-inflammatory potential of formyl-peptide receptor agonists. , 2010, Pharmacology & therapeutics.

[38]  C. Serhan,et al.  Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. , 2010, Circulation research.